Search

INCB7839

It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients. … INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways.

Dinitrochlorobenzene

Dinitrochlorobenzene has been used in trials studying the treatment of HIV Infections.

Lunacalcipol

secretion which may be involved in the etiology of psoriasis. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine

Enzastaurin

Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

AT9283

AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer. … It was discovered and developed internally using Astex’s fragment-based drug discovery platform, Pyramid.

Nalidixic acid

Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

Buthionine sulfoximine

Buthionine sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin).

Diaziquone

Phosphocysteamine

NOX-100

NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.